̽»¨¾«Ñ¡

Several human coronavirus immunotherapy or vaccines have been developed, mainly based on the Spike protein. Genetic analysis shows that the SARS-CoV-2 envelope and receptor binding domain only has a 75% homology with other human coronaviruses, and mutations accumulate in this region. We therefore look at including additional viral proteins that are more genetically conserved. We use the DNA vaccine platform which is a rapid and robust vaccine platform. We generated several chimeric SARS-CoV-2 genes and have selected for the most potent DNA vaccine candidate delivered by in vivo electroporation that protects against SARS-CoV-2 disease in animal models. We have now taken this vaccine to phase I clinical testing.

The partners in the consortium have done this before and all know-how for reliable development is present. KI and FoHM developed the vaccine candidates and infectious models, JLU tested candidates for over-activation of innate immunity, IGEA provided a CE marked device for in vivo electroporation in humans. Northx have produced HQ plasmid for the toxicological studies and GMP plasmid for the phase I clinical study, Adlego/Scantox has performed toxicological testing according to GLP, and Karolinska wrote the IB (Investigator’s brochure) and IMPD (Investigational Medicinal Products Dossier), and obtained ethics committee and EMA. A phase I clinical trial of the vaccine in healthy volunteers is ongoing.

Timeline